N-(2-(5-methoxy-1H-indol-3-yl)ethyl)butyramide | 66012-83-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(2-(5-methoxy-1H-indol-3-yl)ethyl)butyramide
• 英文别名: N-Butyryl-5-methoxytryptamine；N-Butanoyl-5-methoxytryptamine；N-[2-(5-methoxy-1H-indol-3-yl)ethyl]butanamide
• CAS: 66012-83-7
• 化学式: C₁₅H₂₀N₂O₂
• mdl: MFCD01260744
• 分子量: 260.336
• InChiKey: KIHVPIRTWGPOKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  54.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2-(5-methoxy-1H-indol-3-yl)ethyl)butyramide 在 四(三苯基膦)钯 、 potassium acetate 、 sodium hydride 作用下， 以 四氢呋喃 、 二甲胺 为溶剂， 反应 19.0h， 生成 IIK7
  参考文献：
  名称：

  Mapping the Melatonin Receptor. 6. Melatonin Agonists and Antagonists Derived from 6H-Isoindolo[2,1-a]indoles, 5,6-Dihydroindolo[2,1-a]isoquinolines, and 6,7-Dihydro-5H-benzo[c]azepino[2,1-a]indoles

  摘要：

  6H-Isoindolo[2,1-a]indoles (5, 7, 10, 13), 5,6-dihydroindolo[2,1-a]isoquinolines (20, 21), and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles (23, 25, 27, 30) have been prepared as melatonin analogues to investigate the nature of the binding site of the melatonin receptor. The affinity of analogues was determined in a radioligand binding assay using cloned human mt(1) and MT2 receptor subtypes expressed in NIH 3T3 cells. Agonist and antagonist potency was measured using the pigment aggregation response of a clonal line of Xenopus laevis melanophores. The 2-methoxyisoindolo[2,1-a]indoles (7a-d) showed much higher binding affinities than the parent isoindoles (5a-e), and whereas 7a-c were agonists in the functional assay, 7d and 5a-e were antagonists. The 2-ethoxyisoindolo[2,1-a]indoles (10a-d) showed reduced binding affinities compared to their methoxy analogues, while the 5-chloro derivative 13 showed a considerable reduction in binding affinity and potency compared to 7a. The 10-methoxy-5,6-dihydroindolo[2,1-a]isoquinolines (21a-c) had higher binding affinities than the corresponding parent indoloisoquinolines (20a-c) in the human receptor subtypes, and the parent compounds were antagonists whereas the 10-methoxy derivatives were agonists in the functional assay. The N-cyclobutanecarbonyl derivatives of both the parent (20d) and 10-methoxyl (21d) series had similar binding affinities and were both antagonists with similar potencies. The 11-methoxy-6,7-5H-benzo[c]azepino[2,1-a]indoles (25a-d) had higher binding affinities than the corresponding parent compounds (23a-d) at the MT2 receptor but similar affinities at the mt(1) site; all of the compounds were antagonists in the functional assay. Changing 11-methoxy for 11-ethoxy decreased the binding affinity slightly, and this was more evident at the MT2 receptor. All of the derivatives investigated had either the same or a greater affinity for the human MT2 receptor compared to the mt(1) receptor (range 1:1-1:132). This suggests that the mt(1) and MT2 receptor pockets differ in their ability to accommodate alkyl groups in the indole nitrogen region of the melatonin molecule. Two compounds (7c and 25c) were tested in functional assays on recombinant mt(1) and MT2 melatonin receptors. Compound 7c is a potent agonist with some selectivity (44-fold) for the MT2 receptor, while 25c is an MT2-preferring antagonist. Increasing the carbon chain length between N-1 of indole and the 2-phenyl group from n = 1 through n = 3 leads to a fairly regular decrease in the binding affinity, but, remarkably, when n = 3, it converts the methoxy compounds from melatonin agonists to antagonists. The Xenopus melatonin receptor thus cannot accommodate an N-n-alkyl chain attached to a 2-phenyl substituent with n > 2 in the required orientation to induce or stabilize the active receptor conformation.

  DOI：

  10.1021/jm980684+
• 作为产物：
  描述：

  丁酸酐 、 5-甲氧基色胺盐酸盐 在 sodium acetate 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 3.0h， 以73%的产率得到N-(2-(5-methoxy-1H-indol-3-yl)ethyl)butyramide
  参考文献：
  名称：

  2-Amido-8-methoxytetralins: A series of nonindolic melatonin-like agents

  摘要：

  A series of unsubstituted and methoxy-substituted 2-amidotetralins (4a-q) was prepared and evaluated for their ability to compete for 2-[I-125]iodomelatonin binding to chicken retinal membranes and for their potency to inhibit the calcium-dependent release of [H-3]dopamine from rabbit retina. The lead compound, 2-acetamido-8-methoxytetralin (4j), showed a moderate affinity (K(i) = 46 nM) and potency (IC50 = 1.4 nM) at the melatonin receptor. The structural requirements necessary for optimal agonistic activity at the melatonin receptor are as follows. First, the amido group, which should have a small, nonbranched alkyl group, is essential for affinity, and second, the methoxy substituent at the 8-position of the 2-amidotetralin ring is essential for optimal agonistic activity at the melatonin receptor. We concluded that this series of unsubstituted and methoxy-substituted 2-amidotetralins constitutes a class of nonindolic melatonin-like agents that can be used as pharmacological tools to further characterize melatonin receptors and to elucidate the mode of action of melatonin.

  DOI：

  10.1021/jm00072a008

文献信息

• A Nickel(II)‐Mediated Thiocarbonylation Strategy for Carbon Isotope Labeling of Aliphatic Carboxamides
  作者：Simon S. Pedersen、Aske S. Donslund、Jesper H. Mikkelsen、Oskar S. Bakholm、Florian Papp、Kim B. Jensen、Magnus B. F. Gustafsson、Troels Skrydstrup

  DOI：10.1002/chem.202005261

  日期：2021.4.26

  pharmaceutically relevant small molecules and biopharmaceuticals bearing aliphatic carboxamides have been successfully labeled with carbon‐13. Key to the success of this novel carbon isotope labeling technique is the observation that 13C‐labeled NiII‐acyl complexes, formed from a 13CO insertion step with NiII‐alkyl intermediates, rapidly react in less than one minute with 2,2’‐dipyridyl disulfide to quantitatively

  一系列带有脂族羧酰胺的药学上相关的小分子和生物药物已成功用碳13标记。这项新颖的碳同位素标记技术成功的关键在于，观察到13 C标记的Ni II-酰基络合物是由13 CO插入步骤与Ni II-烷基中间体形成的，在不到一分钟的时间内迅速与2,2反应'-二吡啶基二硫化物定量形成相应的2-吡啶基硫酯。使用13 C-SilaCOgen还是使用13C-COgen允许化学计量添加同位素标记的一氧化碳。随后一系列结构多样的胺的单罐酰化反应可提供所需的13 C标记的羧酰胺，收率很高。建议在Ni II-酰基配合物和二硫化物之间形成单电子转移途径，以提供反应性Ni III-酰基硫化物中间体，该中间体迅速经历还原性消除反应，形成所需的硫酯。通过进一步优化反应参数，可以确定仅11分钟的反应时间，从而为探索该化学方法进行碳11同位素标记开辟了可能性。最后，这种同位素标记策略可以适应13的合成C标记的利拉鲁肽和地格曲胰岛素，代表两种抗糖尿病药。
• Potential Radioprotective Agents. 1. Homologs of Melatonin
  作者：Robert T. Blickenstaff、Stephan M. Brandstadter、Shailaja Reddy、Robert Witt

  DOI：10.1002/jps.2600830220

  日期：1994.2

  Homologs of melatonin were prepared by acylation of 5-methoxytryptamine with the appropriate acid chloride or anhydride. The products were administered as solutions or suspensions in soybean oil by ip injection to mice 30 min prior to irradiation with 950 cGy of 6 mV photons. Protection was achieved with all compounds, survival rate being maximal for mice treated with the hexanoic amide 5 and the octanoic

  褪黑激素的同系物通过用适当的酰氯或酸酐酰化5-甲氧基色胺来制备。在用950 cGy的6 mV光子照射之前，通过腹腔注射将产物以大豆油中的溶液或悬浮液的形式给予小鼠30分钟。所有化合物均可实现保护，用己酸酰胺5和辛酸酰胺6处理的小鼠的存活率最高。
• SUBSTITUTED INDOLE MCL-1 INHIBITORS
  申请人：VANDERBILT UNIVERSITY

  公开号：US20160214934A1

  公开（公告）日：2016-07-28

  The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.

  本申请提供了一些化合物，其中包括能够抑制抗凋亡Bcl-2家族蛋白（例如髓系细胞白血病-1（Mcl-1）蛋白）活性的化合物。本发明还提供了制药组合物以及使用所提供化合物治疗由Mcl-1蛋白过度表达或调节失常所致的疾病和病况（例如癌症）的方法。在某些实施例中，所提供的化合物具有公式I的结构。在某些实施例中，所提供的化合物具有公式II的结构。
• HYPNOTIC BETA-CARBOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
  申请人：MACEF

  公开号：EP1064284B1

  公开（公告）日：2002-03-27
• Methods and compositions for treatment of hypertension
  申请人：Czeisler A. Charles

  公开号：US20050137247A1

  公开（公告）日：2005-06-23

  Methods and compositions for treating and/or preventing hypertension are provided. The methods involve administration of melatonin, or an analog thereof, to a subject. The methods and compositions may be used to treat various forms of hypertension, including essential hypertension.